Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study Article
Overview
publication date
- August 19, 2014
published in
- The Lancet Oncology Journal
Identity
Scopus Document Identifier
- 84905872918
Digital Object Identifier (DOI)
- 10.1016/S1470-2045(14)70362-6